Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05864248 | RECRUITING | Heart Diseases

Feasibility Study SA of the Supira System for HRPCI
Sponsor:

Jaggery

Brief Summary:

The objective is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing high-risk percutaneous interventions (HRPCI).

Condition or disease

Heart Diseases

Coronary Artery Disease (CAD)

Heart Failure

Intervention/treatment

Supira System

Phase

NA

Detailed Description:

The Feasibility Study SA is a prospective, single-arm, interventional multi-center study enrolling up to 100 treated subjects. The Supira Catheter is a single-use percutaneous expandable blood pump designed to unload the left ventricle by actively transporting blood from the left ventricle into the aorta. The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option

Study Type : INTERVENTIONAL
Estimated Enrollment : 115 participants
Masking : NONE
Primary Purpose : DEVICE_FEASIBILITY
Official Title : Feasibility Study SA of the Supira System for HRPCI
Actual Study Start Date : 2023-09-13
Estimated Primary Completion Date : 2025-09-30
Estimated Study Completion Date : 2025-09-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
To be eligible, subjects must meet ALL of the following inclusion criteria
  • 1. Age ≥ 18 and ≤ 90 years
  • 2. Will undergo elective or urgent HRPCI, where hemodynamic support is needed, as determined by the institutional Heart Team
  • 3. Signed the informed consent
  • To be eligible, subjects must NOT meet ANY of the following exclusion criteria
    • 1. Cardiogenic shock or acutely decompensated pre-existing chronic heart failure. Cardiogenic shock is defined as: systemic hypotension (systolic BP \< 90 mmHg or the need for inotropes/pressors to maintain a systolic BP \> 90 mmHg) plus one of the following: any requirement for inotropes/pressors prior to arrival at the catheterization laboratory, clinical evidence of end-organ hypoperfusion or use of intra-aortic balloon pump (IABP), or any other circulatory support device.
    • 2. Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
    • 3. Evidence of left ventricular thrombus
    • 4. Moderate or greater aortic valvular disease or regurgitation (≥ 2+ on a 4-grade scale as assessed on transthoracic echo cardiogram (TTE)
    • 5. Moderate or greater aortic stenosis (gradient \>20 mmHg or valve area \< 1.5 cm\^2 as assessed on TTE)
    • 6. Previous aortic valve replacement or reconstruction
    • 7. Ascending or descending aortic dissection or aortic aneurysm \> 4.5 cm
    • 8. Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the device
    • 9. Presence of decompensated liver disease; severe liver dysfunction (Child class C)
    • 10. Patients requiring renal replacement therapy with dialysis
    • 11. Infection of the proposed procedural access site or systemic active infection requiring ongoing antibiotic therapy
    • 12. Current or history of heparin-induced thrombocytopenia (HIT)
    • 13. Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or has known hypersensitivity to heparin, aspirin, ADP receptor inhibitors, or nitinol
    • 14. Known or suspected coagulopathy or abnormal coagulation parameters (defined as platelet count ≤ 100,000/mm³ or spontaneous INR ≥ 1.5 or known fibrinogen ≤ 1.5 g/L)
    • 15. Any condition or scheduled surgery that will require discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure
    • 16. Planned coronary intervention within 30 days post index procedure
    • 17. Breastfeeding or pregnant
    • 18. Currently participating in active follow-up phase of another clinical study of an investigational drug or device
    • 19. Active COVID-related infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
    • 20. Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures
    • 21. Considered to be part of a vulnerable population (defined as individuals with mental disability, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention)
Feasibility Study SA of the Supira System for HRPCI

Location Details

NCT05864248

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

Brazil,

Dante Pazzanese Institute of Cardiology (Dante)

São Paulo, Brazil, 04012-909

RECRUITING

Brazil,

'Heart Institute of São Paulo (Incor)'

São Paulo, Brazil, 5403-000